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Abstract
The tumor suppressor gene p53 is expressed in the contrasting cell fates apoptosis and proliferation. We examined
whether the transactivation of the p53 target genes, waf1 and mdm2, is dependent on the cause of p53 induction in human
 .  .peripheral blood mononuclear cells PBMC . Both apoptosis triggered by the purine analog 2-chlorodeoxyadenosine CdA
 .and growth stimulation by the mitogen phytohemagglutinin PHA induced a comparable level and time course of p53
mRNA expression. Both stimuli led also to an increase of p53 protein levels. The cytotoxic agent, but not the mitogen, led
to transactivation of waf1 and mdm2 within 18 h. Transactivation was followed by apoptosis of 89% of the PBMC within
 .  .48 h. The c-myc oncogene and poly ADP-ribose polymerase PARP , which also have a dual function in proliferation and
apoptosis, showed an early induction by both CdA and PHA. These results add further evidence that growth stimulation and
DNA damage-induced apoptosis share early gene activation pathways in normal cells. However, since p53 does selectively
translate into transactivation of target genes depending on the cause of induction, this function of p53 seems to be regulated
by additional factors, which are closely related to the ultimate fate of the cell. q 1997 Elsevier Science B.V.
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1. Introduction
The p53 tumor suppressor gene is a key player in
the cellular response to DNA damage. DNA damage
activates p53, which in turn induces either growth
arrest primarily in the G phase of the cell cycle or1
w xapoptosis 1,2 . The halting of the cell cycle facili-
tates surveillance of the genome and allows repair of
the damage. If the cells are not prepared to repair the
damage, they are alternatively channeled into apopto-
w xsis 3 . Different factors determine whether a cell
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decides to stop or to die. Growth factors and mem-
bers of the bcl-2 family have been shown to play an
w ximportant role in this decision 4 .
Induction of p53 following DNA damage activates
the transcription of a variety of genes such as waf1
w x w x w x3,5 , mdm2 6 , or bax 7 . Waf1 leads to growth
arrest by acting as a cyclin-CDK inhibitor and
w xPCNA-interacting protein 5,8 . Experiments in p53
‘knock-out’ mice have shown that waf1 induction by
DNA damage is critically dependent on the presence
w xof p53 9 . The role of waf1 for triggering apoptosis
is less clear and radiation-induced apoptosis in the
w xmouse does proceed despite deletion of p21 10 .
DNA damage also increases the levels of mdm2
w x6 . However, rather than being an effector of p53,
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mdm2 is an inhibitor of p53 function. Mdm2 binds to
p53, and this binding inhibits p53 sequence-specific
w xtransactivation 11 . Mdm2 represents a feedback
loop limiting length or severity of the p53-mediated
w xcell cycle arrest following DNA damage 12 . Recent
evidence has shown that mdm2 can inhibit p53-medi-
ated apoptosis probably by abolishing p53-dependent
sequence-specific transcriptional activation.
Seemingly contradictory to its central role in
growth arrest and apoptosis, p53 is also induced
during entrance of quiescent cells into the cell cycle
w x13,14 . When peripheral blood mononuclear cells
 .PBMC are stimulated by the mitogen phytohemag-
 .glutinin PHA , p53 mRNA and protein levels pro-
gressively increase reaching a maximum at the G rS1
transition phase. These levels stay constant at a
w xslightly lower level throughout the S phase 14 . The
function of p53 activation during proliferation is not
clear. We asked the question whether the induction of
known p53 target genes is dependent on the cause of
p53 activation, namely DNA damage or growth stim-
ulation. PBMC were chosen as the model system
since they allow one to look at the physiological
regulation of untransformed human cells ex vivo.
 . w xChlorodeoxyadenosine CdA , a purine analog 15 ,
was used as the DNA damaging agent since this drug
has been described to be a potent inducer of apopto-
w xsis in resting lymphocytes 16 . We show here that
waf1 and mdm2 are induced by DNA damage but not
by growth stimulation despite similar expression of
p53.
2. Materials and methods
2.1. Materials and PBMC culture
PBMC were purified from whole blood of normal
volunteer donors and cultured at 106 per ml in RPMI
1640 medium containing 10% heat-inactivated fetal
bovine serum. CdA was purchased from Lipomed
 .Pharmaceuticals Basel, Switzerland , PHA from
 .Seromed Basel, Switzerland .
2.2. Analysis of DNA integrity
DNA fragmentation was visualized as described
w x17 .
2.3. Northern blot analysis
Total RNA was extracted using the TRIzole RNA
 .isolation kit GIBCO, Grand Island, NY . Total RNA
 .10 mg per sample was fractionated on agarose gels
containing 0.7% formaldehyde and transferred to ny-
 .lon membranes Schleicher and Schuell . Hybridiza-
32 tion with random-primer P-labeled probes 1–2=
6 .10 cpmrml hybridization solution was performed
for 24 h at 428C. Filters were washed to a final
stringency of 0.1% SSC at 658C. Purified inserts
were used as human cDNA probes: mdm2 800 bp,
w x.HindIII; generous gift from Dr. B. Vogelstein 18 ,
wt-p53 2.0 kb, BamHI, purchased from ATCC,
. Rockville, MD , waf1 2.1 kb, BamHIrHindIII, gen-
w x. erous gift from Dr. B. Vogelstein 5 , and c-myc 0.9
.kb, ClaIrXbaI . A 988 bp probe for PARP was
synthesized by PCR using cDNA from normal human
lung as a template. The primers were PARP-5X 5X-
ATGGCGGAGTCTTCGGATAA-3X and PARP-3X
5X-GGTTGGGTGTCTGTGTCTTG-3X. The reaction
 .mixture was preincubated at 948C preheated block
for 3 min before performing 33 PCR cycles. Anneal-
ing was at 578C, elongation at 748C, and denaturation
at 948C, each for 1 min. The PCR reaction mixture
was prepared according to the instructions by the
 .manufacturer AppligenerOncor, Illkirch, France .
2.4. Western blot analysis
Cells were collected and lysed in 80 mM Tris, pH
6.8, 2% SDS, 10% glycerol, 2% 2-b-mercapto-
ethanol, and 0.02% bromophenol blue at 1008C for 3
min. Proteins were size-fractionated on a 12% SDS-
polyacrylamide gel and transferred to a Hybond
nitrocellulose filter using a semidry electroblotting
apparatus. Membranes were probed using a mouse
monoclonal antibody against p53 Ab-6, Oncogene
.Science and visualized using a secondary goat–anti-
mouse antibody conjugated with horseradish peroxi-
dase. Chemoluminescence was performed with ECL
 .Amersham Life Science .
2.5. Flow cytometry
Attached cells were brought into suspension using
5 mM EDTA, pelleted together with detached cells
and washed in cold PBS. The fresh samples were
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Fig. 1. Agarose gel electrophoresis of DNA from PBMC after
 .  .exposure to 10 mgrml PHA P or to 1 mgrml CdA C . Cells
were harvested at the indicated hours after start of treatment.
permeabilized with Triton X-100 at low pH in the
w xpresence of serum proteins 19 . The metachromatic
dye acridine orange was used to identify simultane-
ously G and apoptotic cells by measuring cellular0 –1
DNA and RNA. Intercalated into double-strand DNA,
acridine orange shows green fluorescence, while
dye–RNA interaction shows red fluorescence. Flow
cytometry was performed on a FACScan flow cy-
tometer Becton Dickinson and Co., Mountain View,
.CA and cell populations were quantitated using
CELL QUEST software. Apoptosis was morphologi-
cally confirmed by fluorescent microscopy.
3. Results
3.1. Apoptosis and cell cycle acti˝ation
Parallel PBMC samples from individual normal
donors were exposed to 1 mgrml CdA or to 10
mgrml PHA. The cytotoxic drug CdA induced apop-
tosis within 24–48 h as demonstrated by the typical
internucleosomal DNA fragmentation pattern Fig.
.1 . The mitogen PHA did not induce significant DNA
laddering. To obtain a numeric estimate on the effect
of CdA or PHA on viability and cell cycle distribu-
Fig. 2. Bivariate flow cytometric analysis of PBMC after staining with the metachromatic dye acridine orange. Fresh PBMC from an
individual human donor were treated with 1 mgrml CdA for the indicated duration. Acridine orange allows the simultaneous
 .  .measurement of cellular DNA green fluorescence and RNA red fluorescence . Quiescent G cells show a markedly diminished RNA0
 .  .content compared to G cells. Apoptotic cells Ap are characterized by diminished DNA-associated green fluorescence. The numeric1
results of this analysis are shown in Table 1.
( )M.M. Borner et al.rBiochimica et Biophysica Acta 1358 1997 314–320 317
Table 1
Quantitative analysis of the effects of treatment with 1 mgrml
CdA or 10 mgrml DDP on cell cycle distribution and induction
 .of apoptosis Ap in unstimulated and PHA-stimulated PBMC.
The percentage of cells in the respective cell cycle compartment
after the indicated hours of treatment was calculated and the
results of a representative experiment is shown. Approximately
10 000 acridine orange stained cells were examined for each flow
cytometric analysis
 .Treatment Cell cycle phase Percentage of cells %
24 h 48 h 72 h
Control G 88 79 610
G 4 6 191
S 0 0 0
G 0 0 02
Ap 8 15 20
 .CdA 1 mgrml G 68 21 10
G 6 4 101
S 0 0 0
G 0 0 02
Ap 26 75 89
 .PHA 10 mgrml G 30 27 340
G 26 30 111
S 22 16 21
G 5 7 52
Ap 17 20 29
tion, treated samples were stained with acridine or-
ange and quantified by FACS analysis. Table 1 shows
that the percentage of apoptotic cells increased from
26% to 89% within 48 h of CdA treatment. PHA-
stimulated cells displayed also some apoptotic back-
ground noise. The intensity of the DNA laddering
correlated well with apoptosis quantification by FACS
analysis. Acridine orange allows simultaneous identi-
fication of G , G , and apoptotic cells by DNA and0 1
 .RNA content measurement Fig. 2 . Thus, it could be
demonstrated that most of the CdA-treated PBMC
died in G or at the G rG transition phase of the0 0 1
cell cycle. PHA caused 53% of PBMC to leave the
G compartment of the cell cycle and this stimulatory0
 .effect was beginning to cease after 48 h Table 1 .
3.2. p53, c-myc, and PARP mRNA expression
The tumor suppressor gene p53 has been shown to
be involved in DNA damage control as well as in cell
w xcycle activation 1,13,14 . Other genes with a dual
w xfunction in apoptosis and proliferation are c-myc 20
w xand PARP 21 . To assess the expression of these
genes in apoptosis and proliferation, PBMC were
treated with CdA or PHA, respectively. PBMC from
individual normal donors were used for each set of
experiments to control for variations in gene induc-
tion thresholds and drug sensitivity among individu-
als. The results shown were reproduced in indepen-
 .Fig. 3. Northern blots to show the induced A p53, waf1, mdm2,
 .B PARP, and c-myc mRNA expression in PBMC. Cells were
treated with 10 mgrml PHA, 1 mgrml CdA, or both agents.
Total RNA was harvested at the indicated hours of treatment and
 .equal amounts of RNA 10 mg were electrophoresed on an
agarose-formaldehyde gel. The same filter was stripped several
times and hybridized with the probes indicated. Shown are
autoradiograms and ethidium bromide stained gel A, bottom
.panel .
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Fig. 4. Western blot analysis of p53 protein. Fresh PBMC from an individual human donor were treated with 10 mgrml PHA or 1
mgrml CdA for the indicated time periods. Hundred mg protein prepared from whole cell extracts was analysed on each lane.
dent experiments using different PBMC donors. Both
CdA and PHA led to a similar pattern of p53, c-myc,
and PARP induction with a rapid rise of mRNA
 .within 2 h of exposure Fig. 3AqB . The effect of
CdA was transient since mRNA levels had returned
to baseline levels at 18 h of exposure, while the effect
of PHA was lasting at 18 h. Interestingly, CdA did
abrogate mRNA induction by PHA at 18 h. The
 .strong waf1 and mdm2 induction at 18 h Fig. 3B
makes differences in loading an improbable cause for
the lack of p53, c-myc, and PARP expression after 18
h CdA exposure. Despite comparable c-myc induc-
tion at 2 h by CdA and PHA, this did not translate
into a significant cell cycle activation by CdA Table
.1 .
3.3. Transacti˝ation of waf1 and mdm2 by p53
Wild type p53 can bind to DNA with sequence
w xspecificity and transcriptionally activate waf1 5 and
w x  .mdm2 11 . In our experiments, DNA damage CdA
 .and cell cycle activation PHA led to a parallel
 .induction of p53 mRNA Fig. 3B . Other authors
have shown an increase of p53 protein expression
after both growth stimulation and DNA damage
w x13,22 . In accordance with these results, Fig. 4 shows
that both PHA and CdA led to increasing p53 protein
levels over 48 h of stimulation. Thus, the next step
was to examine the transactivation potential of p53 in
both situations. Only CdA led to significant waf1 and
mdm2 induction, which increased from 2 to 18 h.
The increase of p53 mRNA and protein expression
by PHA was not associated with a significant induc-
 .tion of waf1 and mdm2 Fig. 3AqB .
4. Discussion
These studies show that the transactivation of the
p53 target genes waf1 and mdm2 is not directly
dependent on p53 expression but rather on the cause
of p53 induction. Because of its central role in the
cellular response to DNA damage, p53 has been
w xnamed the guardian of the genome 1 . Waf1 is a
critical effector of the p53-dependent DNA damage
response and orchestrates G arrest to allow damage1
repair before DNA replication is initiated in the S
phase of the cell cycle. In parallel to G arrest, p531
can trigger the apoptotic suicide program and it is
suggested that additional genes such as bcl-2 decide,
w xwhether death or repair prevails 23 .
CdA is a purine analog with equal activity against
w xboth dividing and resting lymphocytes 16 . In resting
lymphocytes, CdA interferes with the repair of spon-
taneously occurring DNA strand breaks resulting in
w xapoptosis 15 . In accordance with its role in DNA
damage control, p53 expression was induced by CdA.
p53 expression was accompanied by waf1 and mdm2
induction and the temporal expression pattern was
compatible with p53 transactivating these target
genes. After a lag period of 24–48 h, CdA-treated
PBMC underwent apoptosis.
The fact that p53 is also induced during prolifera-
tion, seems at first sight incompatible with the central
role of this tumor suppressor gene in growth arrest
w x13,14 . We show here that despite similar temporal
pattern of p53 induction in apoptosis and upon mito-
genic stimulation, the latter did not translate into
significant waf1 or mdm2 transcription. In accor-
dance with our findings, it has been shown, that p53
and mdm2 are expressed independently in serum-
stimulated Swiss mouse 3T3 cells and concanavalin
w xA-stimulated mouse spleen lymphocytes 22 . These
authors have speculated that high mdm2 baseline
mRNA levels or p53 levels below the threshold
necessary for upregulating mdm2 expression might
explain their findings. Our results virtually exclude
the possibility, that the level of p53 mRNA expres-
sion determined its potential for transactivation.
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However, we cannot exclude the possibility, that a
threshold for the transactivatory function of the p53
protein exists, since the protein levels were lower
after PHA stimulation compared to CdA treatment,
although mRNA and protein induction paralleled.
Other authors have shown a similarly increased p53
protein expression after growth stimulation as well as
w xDNA damage 13,22 . Thus, it is unlikely that differ-
ences in the translation of p53 alone were responsible
for this differential waf1 and mdm2 expression.
Another possibility is that additional factors to p53
repress waf1 and mdm2 induction in proliferation or
activate these genes in the DNA damage response.
These putative factors may interact at the posttrans-
lational level with p53 protein or directly affect the
regulatory site of the waf1 and mdm2 gene. In most
systems, DNA damage-elicited waf1 induction seems
to be strictly p53-dependent, since DNA damage does
not induce waf1 expression in p53-deficient cells
w x3,9 . However, there are observations, that higher
doses of DNA damaging agents can circumvent this
absolute requirement for p53, suggesting alternative
w xp53-independent pathways for waf1 induction 9 .
Recently, a discordant protein level and transcrip-
tional activity of p53 in response to radiation has
w xbeen reported, supporting our findings 24 .
Other genes with a dual role in apoptosis and
w xproliferation 14,20,21,25 are c-myc and PARP. As
for p53, we show that these genes are induced by
both CdA and PHA suggesting a functional relation-
ship. PHA led to a longer lasting induction of these
genes than CdA. PHA has been described to produce
a late second peak of c-myc mRNA expression be-
tween 14 and 48 h, possibly due to the interaction of
w xIL2 with its receptor in activated T-cells 14 and it is
possible that the same applies to p53 and PARP.
PARP is involved in DNA repair and the induction of
w xp53 26 . The picture is even more complex, since
PARP itself serves as a substrate for a variety of
cystein proteases known to be activated in apoptosis
w x21,27,28 . Since replicating cells are at an increased
risk for DNA damage, the induction of both PARP
and p53 in this setting might be related to DNA
repair. Our results provide evidence that additional
factors to p53 coregulate the expression of p53 target
genes. Further research will determine whether these
are positively or negatively regulating factors. The
combined effect of PHA and CdA on transactivation
suggests a positively regulating factor for DNA dam-
age and a dominance of this factor over a putative
negatively regulating factor.
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